It is increasingly evident that approval and clinical success of agents treating diabetes can no longer rest on changes in glucose control alone. The ability of a novel therapeutic to effect the complications of diabetes (diabetic nephropathy, retinopathy, wound healing, etc.) may directly relate to its success on the marker. What is clear is that the real cost of the disease, both in financial and physiologic terms, comes from complications that attend uncontrolled or poorly controlled glycemia. Virtually all organ systems are impaired in the face of diabetes.
Charles River is keenly aware of this issue and has been investigating it internally by validating new models of wound healing, examining the effects of diabetes on bone health in rodent models, and ensuring that our histological endpoints of the inflammatory side of diabetes are up to speed with the literature. For more information on this topic, please read our blog titled Diabetes Complications: A Long and Lethal List.